- Home
- MIN vs AVIR Comparison
MIN vs AVIR Comparison
Compare MIN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIN
- AVIR
- Stock Information
- Founded
- MIN 1988
- AVIR 2012
- Country
- MIN United States
- AVIR United States
- Employees
- MIN N/A
- AVIR N/A
- Industry
- MIN Trusts Except Educational Religious and Charitable
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- MIN Finance
- AVIR Health Care
- Exchange
- MIN Nasdaq
- AVIR Nasdaq
- Market Cap
- MIN 310.1M
- AVIR 290.4M
- IPO Year
- MIN N/A
- AVIR 2020
- Fundamental
- Price
- MIN $2.72
- AVIR $3.56
- Analyst Decision
- MIN
- AVIR Hold
- Analyst Count
- MIN 0
- AVIR 1
- Target Price
- MIN N/A
- AVIR $6.88
- AVG Volume (30 Days)
- MIN 331.0K
- AVIR 152.3K
- Earning Date
- MIN 01-01-0001
- AVIR 11-06-2024
- Dividend Yield
- MIN 7.31%
- AVIR N/A
- EPS Growth
- MIN N/A
- AVIR N/A
- EPS
- MIN 0.08
- AVIR N/A
- Revenue
- MIN N/A
- AVIR N/A
- Revenue This Year
- MIN N/A
- AVIR N/A
- Revenue Next Year
- MIN N/A
- AVIR N/A
- P/E Ratio
- MIN $33.38
- AVIR N/A
- Revenue Growth
- MIN N/A
- AVIR N/A
- 52 Week Low
- MIN $2.52
- AVIR $2.77
- 52 Week High
- MIN $2.88
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- MIN 44.73
- AVIR 49.38
- Support Level
- MIN $2.70
- AVIR $3.31
- Resistance Level
- MIN $2.74
- AVIR $3.86
- Average True Range (ATR)
- MIN 0.02
- AVIR 0.12
- MACD
- MIN -0.00
- AVIR 0.03
- Stochastic Oscillator
- MIN 22.89
- AVIR 46.90
About MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).